Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Michela Piezzo
Observed names:
M. Piezzo,
Piezzo, Michela
Institutions:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Fondazione IRCCS Istituto Nazionale dei Tumori
Observed institutions:
Azienda Ospedaliero-Universitaria Cagliari,
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Fondazione IRCCS Istituto Nazionale dei Tumori,
Sapienza University of Rome
ORCID:
0000-0002-1730-3900
Observed ORCID:
0000-0002-1730-3900
OpenAlex ID:
A5057695243
Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
2020
·
Michela Piezzo
, Stefania Cocco
, et al.
·
International Journal of Molecular Sciences
·
231
PDF
Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models
2022
·
Stefania Cocco
, Alessandra Leone
, et al.
·
Journal of Translational Medicine
·
138
PDF
Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
2020
·
Stefania Cocco
, Michela Piezzo
, et al.
·
International Journal of Molecular Sciences
·
137
PDF
Targeting Autophagy in Breast Cancer
2020
·
Stefania Cocco
, Alessandra Leone
, et al.
·
International Journal of Molecular Sciences
·
121
PDF
Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
2020
·
Michela Piezzo
, Paolo Chiodini
, et al.
·
International Journal of Molecular Sciences
·
119
PDF
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients
2017
·
Gerardo Botti
, Francesca Collina
, et al.
·
International Journal of Molecular Sciences
·
103
PDF
Multiple Effects of Ascorbic Acid against Chronic Diseases: Updated Evidence from Preclinical and Clinical Studies
2020
·
Massimiliano Berretta
, Vincenzo Quagliariello
, et al.
·
Antioxidants
·
101
Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis
2024
·
Roberta Caputo
, Giuseppe Buono
, et al.
·
Frontiers in Oncology
·
93
PDF
CAR-T cell therapy for breast cancer: Current status and future perspective
2024
·
Giuseppe Buono
, Monica Capozzi
, et al.
·
Cancer Treatment Reviews
·
31
A Psychosocial Genomics Pilot Study in Oncology for Verifying Clinical, Inflammatory and Psychological Effects of Mind-Body Transformations-Therapy (MBT-T) in Breast Cancer Patients: Preliminary Results
2021
·
Mauro Cozzolino
, Stefania Cocco
, et al.
·
Journal of Clinical Medicine
·
30
PDF
Clinical trials and drug cost savings for Italian health service
2020
·
Francesca D’Ambrosio
, Gianfranco De Feo
, et al.
·
BMC Health Services Research
·
25
PDF
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study
2017
·
M.E. Cazzaniga
, M. Airoldi
, et al.
·
The Breast
·
23
The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies
2021
·
Alberto Enrico Maraolo
, Anna Crispo
, et al.
·
Journal of Clinical Medicine
·
21
PDF
Gene Expression Assay in the Management of Early Breast Cancer
2019
·
Roberta Caputo
, Daniela Cianniello
, et al.
·
Current Medicinal Chemistry
·
16
Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
2021
·
Michela Piezzo
, Roberta D’Aniello
, et al.
·
Pharmaceutics
·
11
PDF
Abstract PS5-03-15: Real-world outcomes with sacituzumab govitecan in patients with triple-negative breast cancer and central nervous system metastases
2026
·
R. Caputo
, M. Piezzo
, et al.
·
Clinical Cancer Research
·
3
307P Overall survival in metastatic breast cancer patients according to different follow up strategies for early breast cancer
2021
·
E. Blondeaux
, L. Boni
, et al.
·
Annals of Oncology
·
2
PDF
Triple-negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study.
2019
·
Giorgio Mustacchi
, Paolo Pronzato
, et al.
·
Journal of Clinical Oncology
·
2
Validation of time to treatment change (TTC) as a surrogate end-point of progression free survival (PFS) for observational trials in metastatic breast cancer patients (MBC): The GIM-13 AMBRA study.
2018
·
Marina Elena Cazzaniga
, Paolo Pronzato
, et al.
·
Journal of Clinical Oncology
·
2
Real-world evidence of sacituzumab govitecan in metastatic triple-negative breast cancer: an updated multicenter analysis
2026
·
R. Caputo
, G. Buono
, et al.
·
ESMO Open
·
1
PDF
Long-term responders to sacituzumab govitecan in metastatic triple-negative breast cancer: Real-world outcomes and predictors from a multicenter Italian cohort.
2026
·
Roberta Caputo
, Giuseppe Buono
, et al.
·
Journal of Clinical Oncology
·
1
354P Sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer patients: A multicenter real-world updated analysis
2025
·
R. Caputo
, M. Piezzo
, et al.
·
ESMO Open
·
1
261P Survival outcomes of triple-negative breast cancer (TNBC) patients in the pre-immunotherapy age: An analysis of Gruppo Italiano Mammella (GIM) 14 BIOMETA study with a focus on biological subtypes
2021
·
L. Cerbone
, E. Blondeaux
, et al.
·
Annals of Oncology
·
1
Clinical Outcomes, Implant Survival, and Complications of Expandable Endoprostheses for Lower Limb Reconstruction in Skeletally Immature Patients with Bone Sarcoma: A Systematic Review and Single-Cohort Meta-Analysis
2026
·
M. Piezzo
, O. Tinelli
, et al.
·
Annals of Surgical Oncology
PDF
Redefining breast cancer treatment by precision oncology: the clinical impact of sacituzumab govitecan
2026
·
Vincenzo Di Lauro
, Paola Claudia Sacco
, et al.
·
Expert Opinion on Biological Therapy
Show more works
View as search
Works count:
54
Citation count:
1,213
H-index:
14
I10-index:
15
Year
Topic
Type